Longitudinal Changes in BDNF and MMP-9 Protein Plasma Levels in Children after Cochlear Implantation

Int J Mol Sci. 2023 Feb 13;24(4):3714. doi: 10.3390/ijms24043714.

Abstract

Congenitally deaf children who undergo cochlear implantation before 1 year of age develop their auditory skills faster than children who are implanted later. In this longitudinal study, a cohort of 59 implanted children were divided into two subgroups according to their ages at implantation-below or above 1 year old-and the plasma levels of matrix metalloproteinase-9 (MMP-9), brain-derived neurotrophic factor (BDNF), and pro-BDNF were measured at 0, 8, and 18 months after cochlear implant activation, while auditory development was simultaneously evaluated using the LittlEARs Questionnaire (LEAQ). A control group consisted of 49 age-matched healthy children. We identified statistically higher BDNF levels at 0 months and at the 18-month follow-ups in the younger subgroup compared to the older one and lower LEAQ scores at 0 months in the younger subgroup. Between the subgroups, there were significant differences in the changes in BDNF levels from 0 to 8 months and in LEAQ scores from 0 to 18 months. The MMP-9 levels significantly decreased from 0 to 18 months and from 0 to 8 months in both subgroups and from 8 to 18 months only in the older one. For all measured protein concentrations, significant differences were identified between the older study subgroup and the age-matched control group.

Keywords: BDNF; MMP-9; auditory development; cochlear implantation; congenital deafness; neuroplasticity.

MeSH terms

  • Brain-Derived Neurotrophic Factor* / blood
  • Brain-Derived Neurotrophic Factor* / chemistry
  • Child
  • Cochlear Implantation*
  • Deafness* / therapy
  • Humans
  • Infant
  • Longitudinal Studies
  • Matrix Metalloproteinase 9* / blood
  • Matrix Metalloproteinase 9* / chemistry

Substances

  • Brain-Derived Neurotrophic Factor
  • Matrix Metalloproteinase 9